CORONA Remedies has delivered a strong FY26 performance, reporting solid revenue and profit growth driven by aggressive brand-building, portfolio expansion, and execution efficiency across operations.

 

The India-focused branded pharmaceutical company posted 17.3% year-on-year revenue growth in FY26 and 20.2% growth in Q4FY26, underscoring sustained momentum across its therapeutic portfolio.

 

Profitability saw an even sharper rise, with PAT growing 33.4% in FY26 and 43.7% in Q4FY26, supported by operating leverage and cost optimisation initiatives.

 

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market. The acquisition was fully funded through internal accruals.

 

Portfolio expansion remained a key theme, with the relaunch of flagship brands Fostine R and Menodac under Women’s Health Therapeutics, alongside Noklot in the Cardiovascular segment, expanding addressable markets.

 

In a further push into high-growth niches, the company has established a dedicated team for the infertility segment.

 

A major milestone was also achieved with two brands crossing Rs. 100 Cr MAT revenue (March 2026), reflecting strengthened brand equity.

 

The company improved its industry position to 27th rank in India, climbing five places over the last three years.

 

Revenue from operations rose to Rs. 1,403.2 Cr in FY26, compared to Rs. 1,196.4 Cr in FY25.

 

EBITDA increased to Rs. 293.4 Cr, while PAT stood at Rs. 199.4 Cr, reflecting strong underlying profitability despite a one-time statutory impact from the New Labour Code.

 

Margins also improved, with PAT margin expanding to 14.2% in FY26, up from 12.5% in FY25.

 

Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: "FY26 has been a strong year for CORONA Remedies, marked by consistent revenue growth and enhanced operational efficiency. Our strategic focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning.

 

"With strategic initiatives like acquisition of WOKADINE and global accreditations, we are well-positioned to drive sustainable growth in years to come."

 

The company’s expansion strategy included leveraging the Bayer-Zydus portfolio through brand relaunches and strengthening its presence in chronic therapies, which contributed approximately 72% of total revenue.

 

Manufacturing and regulatory capabilities also received a boost, with EAEU-GMP certification enabling entry into Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan markets.